 Home > Active Ingredient News > Antitumor Therapy > ESMO directly attacks the immunoneoadjuvant therapy vs adjuvant therapy, and the perioperative exploration of melanoma

ESMO directly attacks the immunoneoadjuvant therapy vs adjuvant therapy, and the perioperative exploration of melanoma

 Last Update: 2022-10-03
 Source: Internet
 Author: User

Tags

what 1 3 200

phase engineering

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

preface

The 2022 European Society for Internal Oncology (ESMO) Annual Meeting was held

Adjuvant therapy is currently used in patients with resectable stage IIB-III melanoma and partially resectable stage IV melanoma, and adjuvant therapy options mainly include targeted and immunotherapy

SWOG S1801 is a randomized phase II study

A total of 313 patients were included in the randomization grouping, 154 received NAT, and 159 received AT

Thirty-six deaths (NAT=14, AT=22) were observed, with a total survival HR of 0.

The same proportion of patients in both groups received adjuvant therapy with pabolizumab after surgery

The results of the SWOG S1801 study showed that neoadjuvant therapy with Pabolizumab improved EFS in high-risk resectable melanoma compared with adjuvant therapy with pabolizumab
.

References:

S.
Patel，et al.
Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801).
2022 ESMO.
Abstract LBA6.

Editor/Typesetting: Jiang Zhou

Execution: Small Garden

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.